Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

Trial Details

NCT ID

NCT07109323

Phase

PHASE1 / PHASE2

Sponsor

Institute of Hematology & Blood Diseases Hospital, China

Status

RECRUITING

Cancer Type

Leukemia

Interventions

• BCMA CART

Locations (sample)

• Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

• Subjects must meet all of the following criteria to be enrolled:
• Ultra high risk mm (UHR-MM), 18-70 years old, suitable for ASCT. And meet any of the following definitions of UHR-MM: 1) cytogenetic ultra-high ris…
• The subjects voluntarily participated in the study and signed the informed consent form (ICF) by themselves or their legal guardians;
• The subject must have proper organ function and meet all the following inspection results:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.